AR and prostate cancer: Directly derived from the Pten-Pb-Cre mouse prostate cancer model [12], the PTEN-P2 and PTEN-CaP2 cell lines were chosen as an initial in vitro prostate cancer model to test the efficacy of DR17 that targets the PTEN/PI3K/AKT and AR pathways.